Management of High-Grade T1 Bladder Tumors

Initial Management

The National Comprehensive Cancer Network recommends a repeat transurethral resection of bladder tumor (TURBT) within 2-6 weeks of the initial resection for all high-grade T1 tumors, even if the initial resection appeared complete 1, 2
Repeat TURBT significantly improves 3-year recurrence-free survival (69% vs 37%) compared to no repeat TURBT 3
The National Comprehensive Cancer Network suggests that repeat TURBT is particularly important for high-risk features such as high-grade T1 tumors, cases where complete resection is uncertain, when no muscle is present in the specimen, and when lymphovascular invasion is present 1, 2, 4

The National Comprehensive Cancer Network recommends intravesical BCG immunotherapy as the preferred treatment after repeat TURBT, with a category 1 recommendation 3, 4
BCG should be administered once weekly for 6 weeks, followed by a rest period of 4-6 weeks, with evaluation at 12 weeks after starting therapy 1
Maintenance BCG therapy should follow the induction course to further reduce recurrence risk 4

Multiple meta-analyses confirm that BCG after TURBT is superior to TURBT alone or TURBT with chemotherapy in preventing recurrences of high-grade Ta and T1 tumors 4, 5
Studies show that BCG therapy can reduce mortality by 23% in eligible patients 5

The National Comprehensive Cancer Network recommends urinary cytology and cystoscopy every 3 months for the first 2 years 2, 4, 6
Imaging of the upper tract should be considered every 1-2 years for high-grade tumors 2, 4
Urine molecular tests for urothelial tumor markers may be considered during surveillance (category 2B recommendation) 4

BCG can cause local irritative symptoms and flu-like symptoms lasting 48-72 hours 5
Management of side effects with single-dose, short-term quinolones and/or anticholinergics can reduce adverse events 5
If BCG is not tolerated, intravesical mitomycin C may be considered as an alternative, though it is less effective 1, 3

For patients with particularly high-risk T1 disease, early cystectomy should be considered due to high risk of progression 2, 3
The 3-year recurrence-free survival rate with repeat TURBT followed by BCG is significantly higher than with a single TURBT (69% vs 37%) 3